Valinor
Private Company
Total funding raised: $15M
Overview
Valinor is an AI/ML biotech startup focused on revolutionizing clinical drug development by creating multi-modal virtual patient models. The company integrates diverse data types—including multi-omics, clinical assays, and imaging—into longitudinal patient profiles to predict therapeutic outcomes before human trials begin. By simulating patient-level responses, Valinor seeks to transform the high-failure paradigm of clinical trials, potentially saving significant time and cost for pharmaceutical partners. Its approach represents a shift from modeling isolated cellular behavior to a holistic, systems-level prediction of drug efficacy and safety.
Technology Platform
A machine learning platform that integrates multi-modal, longitudinal patient data (multi-omics, clinical assays, imaging) to generate virtual patient models for simulating therapeutic efficacy and de-risking clinical trials.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Valinor competes in the broad AI/ML drug discovery and development sector, which includes companies like Recursion, Exscientia, and Insilico Medicine. Its specific focus on virtual patient models for clinical trial simulation places it against firms like Unlearn.AI (digital twins) and companies with clinical prediction platforms. Differentiation hinges on the breadth of integrated data modalities and the whole-patient level of simulation.